Tesamorelin
Contents
What is Tesamorelin?
Tesamorelin is a long-acting GHRH analog approved for reducing excess visceral fat in individuals with HIV-associated lipodystrophy. It has demonstrated targeted fat-reducing effects without direct growth hormone replacement.
How Does Tesamorelin Work?
Tesamorelin stimulates growth hormone release, which in turn increases fat breakdown, particularly visceral fat, which is the fat around inner organs such as the kidneys. This selective action reduces abdominal fat while preserving lean mass.
What is Tesamorelin Used for?
Tesamorelin is approved by the FDA for use in HIV-associated lipodystrophy, which describes an abnormal distribution of fat that occurs as a side effect of the medications taken by people with HIV.
Tesamorelin is being researched for potentially reducing visceral fat (the fat found around internal organs, such as the kidneys). Visceral fat is associated with ill health effects, such as cardiovascular disease.
Other research interests include:
- Age-related growth hormone decline
- Improving sleep quality and recovery after workouts
- General metabolic health
Side Effects and Safety Considerations
Side effects include injection site reactions, fluid retention, and mild joint discomfort. Tesamorelin may increase blood sugar in some individuals.
Tesamorelin Dosing Protocol (for Research)
Research protocols for tesamorelin are varied. Below is one common protocol used in the research setting. Research applications are for below the skin (subcutaneous) administration.
- 1Weeks 1-2: 0.5 mg every night
- 2Weeks 3-4: 1 mg every night
- 3Weeks 5 and beyond: 2 mg every night
Recommended Tesamorelin Source (for Research)
